Elisabetta Zanatta (Italy)
University of Padova
Department of Medicine
27/09/2011- Degree in Medicine and Surgery, University of Padua 17/07/2017- She completed the residency program in Rheumatology, University of Verona From 10/2017 to 10/2020 – PhD in Clinical and Experimental Sciences, Curriculum of Rheumatological and Laboratory Sciences (33rd cycle), Department of Medicine, University of Padua. From March to October 2019 – Research Fellow in the third level center for Systemic Sclerosis of the Cochin hospital in Paris (Prof Yannick-Allanore). In November 2021 – achievement of the 1st level annual Master in Basic and Advanced Echocardiography, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua. From 10/2017 head of the Systemic Sclerosis Clinic, where she follows a court of 450 patients. From January 2020 to today she has directed the multidisciplinary cardio-rheumatological clinic for patients with pulmonary arterial hypertension in connective tissue diseases. Since April 2022 Full-time researcher at the Department of Medicine, University of Padua (Head Prof. Andrea Doria). She is the author of 57 publications in international journals (h index scopus 16, citations 631). She has participated as a speaker in over 40 national and international congresses.

Presenter of 4 Presentations

 Conference Calendar

Management of ILD with and without progressive pulmonary fibrosis in ARDs

Session Name
0280 - Sponsored Session 02 (not included in the main event CME/CPD credit) (ID 16)
Session Type
Sponsored Session
Date
Fri, 17.03.2023
Session Time
08:30 - 09:00
Room
Sala 500
Presenter
Lecture Time
08:30 - 08:55

Case Presentation

Session Name
0860 - Curbside Consult 03: Systemic Sclerosis (ID 56)
Session Type
Curbside Consults
Date
Sat, 18.03.2023
Session Time
14:15 - 15:00
Room
Sala 500
Presenter
Lecture Time
14:15 - 14:30

Q&A

Session Name
0280 - Sponsored Session 02 (not included in the main event CME/CPD credit) (ID 16)
Session Type
Sponsored Session
Date
Fri, 17.03.2023
Session Time
08:30 - 09:00
Room
Sala 500
Presenter
Lecture Time
08:55 - 09:00

PROGRESSIVE ILD IN IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTICENTRE STUDY

Session Name
0450 - Free Communications 04: APS and Other CTDs (ID 26)
Session Type
Free Communications
Date
Fri, 17.03.2023
Session Time
11:50 - 12:50
Room
Sala Londra
Presenter
Lecture Time
12:20 - 12:30

Abstract

Background and Aims

Interstitial lung disease (ILD) is a frequent organ involvement in idiopathic inflammatory myopathies (IIMs). Some patients with ILD may develop a progressive fibrosing phenotype despite treatment. The occurence of progressive IIMs-ILD and the associated phenotype remain to be determined. We aimed to investigate the prevalence, clinical/serological, and functional/radiological characteristics of patients with progressive IIMs-ILD.

Methods

We collected clinical, serological and functional/radiological data of 125 IIMs-ILD patients at diagnosis and follow-up. The prevalent radiological pattern at diagnostic high-resolution CT scans (ground-glass opacities, GGO; fibrotic changes, FC; consolidation, C) was evaluated by expert radiologists. Progression was defined in presence of at least two of these characteristics at one-year follow-up: decline in forced vital capacity (FVC)% pred.≥ 5%, worsening of HRCT or worsening of clinical symptoms.

Results

In 78/125 (62%, 55 females) IIMs-ILD patients, functional and radiological data were available after one-year follow-up. The predominant HRCT pattern was GGO (n=39; 50%), followed by FC (n=22, 28%) and C (n=17, 22%). At one-year follow-up, 14 (18%) patients had developed progressive ILD, whereas 65 (82%) were stable. Demographics, functional data and radiological pattern at ILD diagnosis did not differ between progressors vs. stable IIMs-ILD patients, as well as treatment with glucocorticoids and immunosuppressants. Anti-MDA5 autoantibodies [OR 6.10, 95%CI(1.30–28.4)], heliotropic rash [8.00(1.55–41.23)], and xerostomia [8.19 (1.84 – 36.36)] were progression-associated factors at univariate but not at multivariate analysis.

Conclusions

Progressive ILD occurred in one fifth of our IIMs-ILD cohort. Our results suggest that all patients with IIMs-ILD should be monitored to detect progression, independently of IIMs- and ILD-specific features.

Hide